ECSP12011578A - Composiciones farmacéuticas y formas sólidas - Google Patents

Composiciones farmacéuticas y formas sólidas

Info

Publication number
ECSP12011578A
ECSP12011578A EC2012011578A ECSP12011578A ECSP12011578A EC SP12011578 A ECSP12011578 A EC SP12011578A EC 2012011578 A EC2012011578 A EC 2012011578A EC SP12011578 A ECSP12011578 A EC SP12011578A EC SP12011578 A ECSP12011578 A EC SP12011578A
Authority
EC
Ecuador
Prior art keywords
methyl
naphthalen
yloxy
pyrimidin
trifluoro
Prior art date
Application number
EC2012011578A
Other languages
English (en)
Inventor
Mahavir Prashad
Josef Gottfried Meingassner
Bin Hu
Jorg Berghausen
Stéphanie Monnier
Anton Stuetz
Michael Herbig
Matthias Napp
Claire Haug
Stephane Jonat
Rajender Leleti
Ranjit Thakur
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12011578A publication Critical patent/ECSP12011578A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas de la (3-trifluoro-metil-fenil)-amida del ácido 6-(6-hidroxi-metil-pirimidin-4-iloxi)-naftalen-1-carboxílico, al uso de la (3-trifluoro-metil-fenil)-amida del ácido 6-(6-hidroxi-metil-pirimidin-4-iloxi)-naftalen-1-carboxílico, y a composiciones de la (3-trifluoro-metil-fenil)-amida del ácido 6-(6-hidroxi-metil-pirimidin-4-iloxi)-naftalen-1-carboxílico, en aplicaciones terapéuticas, en especial en las indicaciones con una desregulación/sobre-expresión del factor de crecimiento endotelial vascular (VEGF), (neo)-vascularización, y angiogénesis impulsada por el factor de crecimiento endotelial vascular (VEGF), y a métodos para la elaboración de estas composiciones; la invención se refiere además a las formas específicas de la (3-trifluoro-metil-fenil)-amida del ácido 6-(6-hidroxi-metil-pirimidin-4-iloxi)-naftalen-1-carboxílico, y a la elaboración y el uso de estas formas. La presente invención también se refiere a un nuevo proceso para producir la (3-trifluoro-metil-fenil)-amida del ácido 6-(6-hidroxi-metil-pirimidin-4-iloxi)-naftalen-1-carboxílico.
EC2012011578A 2009-07-06 2012-01-06 Composiciones farmacéuticas y formas sólidas ECSP12011578A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22326909P 2009-07-06 2009-07-06

Publications (1)

Publication Number Publication Date
ECSP12011578A true ECSP12011578A (es) 2012-02-29

Family

ID=42686504

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011578A ECSP12011578A (es) 2009-07-06 2012-01-06 Composiciones farmacéuticas y formas sólidas

Country Status (20)

Country Link
US (1) US20110112121A1 (es)
EP (1) EP2451458A2 (es)
JP (1) JP2012532183A (es)
KR (1) KR20120041745A (es)
CN (1) CN102470134A (es)
AR (1) AR077549A1 (es)
AU (1) AU2010270361A1 (es)
BR (1) BR112012000383A2 (es)
CA (1) CA2767440A1 (es)
CO (1) CO6480987A2 (es)
EA (1) EA201200095A1 (es)
EC (1) ECSP12011578A (es)
IL (1) IL217329A0 (es)
MA (1) MA33417B1 (es)
MX (1) MX2012000391A (es)
SG (1) SG176955A1 (es)
TN (1) TN2011000653A1 (es)
TW (1) TW201113258A (es)
WO (1) WO2011003858A2 (es)
ZA (1) ZA201200079B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2183273T (pt) 2007-08-17 2017-05-22 Novartis Ag Depsipéptidos cíclicos
US8680054B2 (en) * 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
AR086168A1 (es) 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
CN104860885B (zh) * 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
SE1751461A1 (en) * 2017-11-28 2019-05-29 Ascilion Ab Method of detecting an exogenous agent in interstitial fluid
WO2019126270A1 (en) * 2017-12-20 2019-06-27 Sienna Biopharmaceuticals, Inc. Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
ATE415396T1 (de) * 2000-09-20 2008-12-15 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
ATE399766T1 (de) * 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
KR20140025610A (ko) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
EP2451458A2 (en) 2012-05-16
WO2011003858A2 (en) 2011-01-13
CN102470134A (zh) 2012-05-23
CA2767440A1 (en) 2011-01-13
AU2010270361A1 (en) 2012-01-19
MX2012000391A (es) 2012-02-28
WO2011003858A3 (en) 2011-03-03
MA33417B1 (fr) 2012-07-03
US20110112121A1 (en) 2011-05-12
CO6480987A2 (es) 2012-07-16
BR112012000383A2 (pt) 2016-03-29
KR20120041745A (ko) 2012-05-02
JP2012532183A (ja) 2012-12-13
SG176955A1 (en) 2012-01-30
TW201113258A (en) 2011-04-16
IL217329A0 (en) 2012-02-29
ZA201200079B (en) 2012-09-26
EA201200095A1 (ru) 2012-08-30
TN2011000653A1 (en) 2013-05-24
AR077549A1 (es) 2011-09-07

Similar Documents

Publication Publication Date Title
ECSP12011578A (es) Composiciones farmacéuticas y formas sólidas
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
ECSP14013325A (es) Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
CR20120464A (es) Anticuerpos bivalentes biespecíficos anti-vefg/anti-ang-2
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
MX2013012289A (es) Triazolopiridinas.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
RU2011134931A (ru) Штамм enterococcus, используемый для приготовления кисломолочных напитков
ECSP11011483A (es) Piperidinas sustituidas
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
EA201290077A1 (ru) Соединения-801
LT2013016A (lt) Aktyvuotos-potencijuotos formos antikūno poveikio padidinimo būdas
MY155952A (en) Process for the production of artemisinin intermediates
CR20110627A (es) Piperidinas sustituidas
MX349514B (es) Agentes de reversion anticoagulante.
CO6831974A2 (es) Usos, métodos y composiciones biológicas del genero paecilomyces para el control, prevención y erradicación de fitoparásitos en cultivos de solanáceas
FI20106293A0 (fi) Uudet farmaseuttiset koostumukset
EP2563785A4 (en) Compounds as Agonists Against S1P1 Receptors
UA111139C2 (uk) Тверді фармацевтичні композиції і способи їхнього отримання
MY171206A (en) A method of increasing the effect of an activated-potentiated form of an antibody
TN2013000426A1 (en) Triazolopyridines
RU2012102573A (ru) Ангоб